Scarica l'app Stockscreener
200.87
1.40%
-2.86
Pre-mercato:
200.87
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PODD Giù?
Forum
Previsione
Insulet Corp Borsa (PODD) Ultime notizie
Is Insulet Corporation (PODD) One of the Most Oversold Healthcare Stocks to Invest In? - Yahoo Finance
Insulet Corp. stock underperforms Monday when compared to competitors - MarketWatch
Why Insulet (PODD) is a Top Growth Stock for the Long-Term - Yahoo Finance
Should You Investigate Insulet Corporation (NASDAQ:PODD) At US$204? - Moomoo
Insulet Taps Mike Panos As CCO While Shares Trade Below Targets - Yahoo Finance
Analysts see 75% upside on Insulet Corporation (PODD) despite weak share price momentum - MSN
Insulet Corp stock (US45784P1012): Is tubeless insulin delivery strong enough to unlock new upside? - AD HOC NEWS
Insulet stock (US45784P1012): Is the Omnipod edge strong enough to unlock new upside? - AD HOC NEWS
Short Interest in Insulet Corporation (NASDAQ:PODD) Rises By 19.3% - MarketBeat
Insulet Corp. stock rises Friday, still underperforms market - MarketWatch
Truist maintains Insulet Corporation (PODD) buy rating despite device correction announcement - MSN
Insulet Corporation Appoints Mike Panos as Chief Commercial Officer - HarianBasis.co
Citi Flags Competitive Pressure as Key Risk for Insulet Corporation (PODD) - Yahoo Finance
Insulet Corp. Stock Hits 52-Week Low at USD 197.63 Amid Challenges - Markets Mojo
KBC Group NV Grows Stock Position in Insulet Corporation $PODD - MarketBeat
Lbp Am Sa Grows Position in Insulet Corporation $PODD - MarketBeat
PODD Forecast, Price Target & Analyst Ratings | INSULET CORP (NASDAQ:PODD) - ChartMill
Insulet (PODD) down 8.2% since last earnings report: Can it rebound? - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insulet CorporationPODD - ChartMill
PODD Investor Alert: Insulet Corp. Potential Securities - GlobeNewswire
Insulet Faces Omnipod 5 Correction While Shares Trade Below Targets - Sahm
BTIG Maintains Buy Rating on Insulet (PODD) - Insider Monkey
Truist Financial Has Lowered Expectations for Insulet (NASDAQ:PODD) Stock Price - MarketBeat
PODD Investor Alert: Insulet Corp. Potential Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Device Defect: Levi & Korsinsky - Morningstar
Truist Cuts Price Target on Insulet to $315 From $360, Keeps Buy Rating - marketscreener.com
Patton Fund Management Inc. Reduces Holdings in Insulet Corporation $PODD - MarketBeat
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
Evercore Reiterates Outperform Rating for Insulet Corp. (PODD) - Insider Monkey
RBC Cuts Price Target on Insulet to $325 From $380, Keeps Outperform Rating - marketscreener.com
Insulet (NASDAQ:PODD) Reaches New 1-Year Low on Analyst Downgrade - MarketBeat
BTIG Research Lowers Insulet (NASDAQ:PODD) Price Target to $320.00 - MarketBeat
BTIG Maintains Insulet(PODD.US) With Buy Rating, Cuts Target Price to $320 - Moomoo
BTIG Research Adjusts Insulet Price Target to $320 From $380, Maintains Buy Rating - marketscreener.com
Robeco Institutional Asset Management B.V. Increases Stock Position in Insulet Corporation $PODD - MarketBeat
Baillie Gifford & Co. Trims Stock Position in Insulet Corporation $PODD - MarketBeat
A Look At Insulet (PODD) Valuation After Mike Panos Joins As Chief Commercial Officer - Sahm
Liquidity Mapping Around (PODD) Price Events - Stock Traders Daily
Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer - MSN
Insulet Corp. stock falls to new 52-week low - MarketWatch
Insulet stock (US45784P1012): Is its tubeless insulin tech strong enough to unlock new upside? - AD HOC NEWS
Insulet Taps Mike Panos To Drive Omnipod Commercial Execution And Growth - Yahoo Finance Australia
A Look At Insulet (PODD) Valuation After Recent Share Price Weakness - Yahoo Finance
New Commercial Chief and Closed-Loop Progress Might Change The Case For Investing In Insulet (PODD) - simplywall.st
Analysts See 75% Upside on Insulet Corporation (PODD) Despite Weak Share Price Momentum - Insider Monkey
Insulet stock: What investors need to know amid diabetes tech boom - AD HOC NEWS
Insulet Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Insulet Corp. Hits 52-Week Low at USD 199.53 Amid Market Challenges - Markets Mojo
Goldman Sachs Adjusts Price Target on Insulet to $277 From $326, Maintains Buy Rating - marketscreener.com
Insulet Corporation (NASDAQ:PODD) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Insulet Corporation stock hits 52-week low at 199.53 USD By Investing.com - Investing.com Australia
Insulet Corporation (PODD) Stock forecasts - Yahoo Finance UK
Insulet (PODD) Gets Downgraded by Citigroup; Price Target Lowere - GuruFocus
Insulet (PODD) Gets Downgraded by Citigroup; Price Target Lowered | PODD Stock News - GuruFocus
Insulet (PODD) Appoints Mike Panos as Chief Commercial Officer - Insider Monkey
Insulet Corporation stock hits 52-week low at 199.53 USD - Investing.com
Insulet (NASDAQ:PODD) Cut to Neutral at Citigroup - MarketBeat
Citigroup Downgrades Insulet to Neutral From Buy, Adjusts Price Target to $230 From $338 - Moomoo
Citi Downgrades Insulet Corporation (PODD) to Neutral - StreetInsider
0.74%
1.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):